Browse treatments

…h several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanced NSCLC. While this cost asy…

…anges in [18F] FDG uptake in other organs (figure 2).Conclusion Chemoradiotherapy has adverse effects on the vasculature, possibly through increa…

…removed anal tumours with margins ≤1 mm will receive lower dose chemoradiotherapy, while participants with anal tumours with margins >1 mm will b…

…durvalumab and pembrolizumab and consolidation durvalumab after chemoradiotherapy. The study employed 1-month simulation cycles over a lifetime. …

…ssion was used to assess the association of MDT discussion with neoadjuvant treatment.Results Baseline characteristics are summarized in table 1. Ove…

…) presents significant nutritional challenges during concurrent chemoradiotherapy, adversely affecting treatment outcomes and quality of life. No…

…ecurrence involving the sympathetic chain. Following concurrent chemoradiotherapy, pain improved and the patient returned to work. Posture-depend…

…ase II study by Ottenhof et al evaluated 33 patients undergoing chemoradiotherapy as primary treatment for locoregionally advanced PeCa. They rep…

…South Africa, often presenting at advanced stages and requiring chemoradiotherapy. In South Africa, the burden is disproportionately high among w…

…and anti-Hu antibody positivity. She was treated initially with chemoradiotherapy leading to cancer remission but progression of her neurological…

…wed up according to the protocol for 180 days after the initial multi-ion therapy irradiation.Ethics and dissemination The study protocol has bee…